TrialLancet (London, England)2021

Rituximab versus tocilizumab in anti-TNF inadequate responder patients with rheumatoid arthritis (R4RA): 16-week outcomes of a stratified, biopsy-driven, multicentre, open-label, phase 4 randomised controlled trial.

Frances Humby et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.